12.04.2011 • News • Merck & Co. • Merck • Merck Serono

Merck KGaA Eyes Job Cuts at Drugs Unit

Germany's Merck KGaA  is mulling job cuts at prescription drug unit Merck Serono to save costs, the Financial Times Deutschland newspaper reported, citing company sources.

Cutbacks could affect the unit's Swiss headquarters in particular, the paper added.

Stefan Oschmann took over Merck's prescription drug unit Merck Serono on Jan. 1 after the unit saw a string of setbacks in product development.

The European drugs watchdog on Sept. 24 dealt the German family controlled group a blow by advising against the oral multiple-sclerosis treatment cladribine in the drug's potentially largest market.

Global drugmakers, including Merck & Co, Roche and Novartis, have announced job cuts as approvals for new products are slowing while key drugs are losing patent protection.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Top-Feature

most read